Banco Santander S.A. Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Banco Santander S.A. raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 23.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 98,027 shares of the pharmaceutical company’s stock after acquiring an additional 18,621 shares during the period. Banco Santander S.A.’s holdings in Vertex Pharmaceuticals were worth $44,442,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in the business. Swiss RE Ltd. acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $28,000. Eagle Bay Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $29,000. IMG Wealth Management Inc. grew its stake in shares of Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 50 shares during the period. Colonial Trust Co SC boosted its holdings in Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 38 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in Vertex Pharmaceuticals during the fourth quarter worth $33,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $444.92 on Friday. The business’s 50 day moving average price is $437.14 and its 200-day moving average price is $452.33. The firm has a market capitalization of $112.92 billion, a PE ratio of 26.39, a P/E/G ratio of 1.90 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. The firm had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the company posted $4.06 earnings per share. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current year.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
• Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
• Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
• Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

Insider Transactions at Vertex Pharmaceuticals

In other news, Director Sangeeta N. Bhatia sold 318 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $423.73, for a total value of $134,746.14. Following the sale, the director directly owned 4,924 shares of the company’s stock, valued at $2,086,446.52. The trade was a 6.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joy Liu sold 1,104 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the sale, the executive vice president directly owned 20,729 shares in the company, valued at $8,810,239.58. This represents a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 11,133 shares of company stock valued at $4,973,106 over the last ninety days. Insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on VRTX shares. Cantor Fitzgerald reissued an “overweight” rating and set a $590.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Truist Financial began coverage on shares of Vertex Pharmaceuticals in a research note on Wednesday, May 27th. They set a “buy” rating and a $542.00 target price on the stock. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, May 18th. HC Wainwright increased their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Finally, Oppenheimer increased their target price on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Twenty-two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $555.91.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.